<?xml version="1.0" encoding="UTF-8"?>
<p>In 2005, Brazil began negotiations to issue a compulsory license for kaletra (a second-line antiretroviral drug). Eventually the threat of this compulsory license led to an agreement with the patent holder, Abbott, to reduce the price of the drug [
 <xref ref-type="bibr" rid="CR8">8</xref>].
</p>
